OBS'CEREVANCE: French Cohort of Pediatric Autoimmune Cytopenia
Recruiting
Observational Study
Immune Thrombocytopenia
Autoimmune Hemolytic Anemia
Evans Syndrome
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- Up to 17
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,500 (estimated)
- Sponsor
- University Hospital, Bordeaux · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
From 2004, OBS'CEREVANCE is a national real-world prospective clinical cohort of patients with auto-immune cytopenia of pediatric-onset : Immune thrombocytopenia (ITP), Autoimmune Hemolytic anemia (AIHA), or Evans syndrome (all bi or tri cytopenias). Thanks to the collaboration of the 30 French pediatric hematologic centers, this cohort supports all of the Rare Disease Centre CEREVANCE (Centre de …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Diagnosis of ITP, AIHA, Evans Syndrome
* Onset before the age of 18
Exclusion Criteria:
* Opposition of legal representative or to data collection
Contacts